EUCTR2021-005200-35-IT招募中1 期
A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II - NA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participants aged =2 to <6 years (Cohort A) or =6 to <17 years (Cohort B)
- •2. Confirmed diagnosis of MPS II (for Cohort A, nMPS II; for Cohort B, nnMPS II)
- •3. Be on maintenance enzyme replacement therapy (ERT) and have tolerated idursulfase for a minimum of 4 months prior to screening
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have a documented mutation of other genes or genetic diagnosis accounting for developmental delay
- •2. Previously received an IDS gene therapy or stem cell therapy
- •3. Received any CNS-targeted MPS ERT within 6 months prior to screening
- •4. Have a contraindication for lumbar punctures and/or magnetic resonance imaging (MRIs)
- •5. Participated in any other investigational drug study or used an investigational drug within 60 days prior to screening or intend to receive another investigational drug during the study
研究者
相似试验
进行中（未招募）
1 期
Study to determine effectiveness and safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Hunter SyndromeMucopolysaccharidosis Type II [MPS II]EUCTR2021-005200-35-FRDenali Therapeutics Inc.54
招募中
2 期
A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type IIHunter syndromeMucopolysaccharidosis Type II (MPS II)10029305NL-OMON53946Denali Therapeutics Inc.3
招募中
1 期
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non Neuronopathic Mucopolysaccharidosis Type IIMucopolysaccharidosis Type II [MPS II]EUCTR2021-005200-35-SEDenali Therapeutics Inc.54
进行中（未招募）
1 期
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa(DNL310) vs Idursulfase in Pediatric and Young Adult ParticipantsWith Neuronopathic or Non Neuronopathic Mucopolysaccharidosis Type IIEUCTR2021-005200-35-BEDenali Therapeutics Inc.54
进行中（未招募）
1 期
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type IIMucopolysaccharidosis Type II [MPS II]EUCTR2021-005200-35-NLDenali Therapeutics Inc.54